ERBB2 and non-small cell lung carcinoma: A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-tumor Efficacy of DZD9008 in Patients with Advanced NSCLC with EGFR or HER2 Mutation